Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Vaena, Daniel
KEYNOTE-D74, NCT05911295: Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2	Recruiting	3	700	Europe, Canada, US, RoW	disitamab vedotin, RC48, RC48-ADC, pembrolizumab, KEYTRUDA®, gemcitabine, Gemzar, cisplatin, carboplatin	Seagen Inc., RemeGen Co., Ltd., Merck Sharp & Dohme LLC	Urothelial Carcinoma	06/26	04/29
INCLINE-101, NCT05399654: A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors	Active, not recruiting	1/2	72	US, RoW	TAC-001	Tallac Therapeutics	Advanced or Metastatic Solid Tumors	01/26	05/26
Adams, Rachel
No trials found